Renalytix (LON:RENX) Stock Jumps 1.8% – Here’s Why

Renalytix Plc (LON:RENX)’s share price shot up 1.8% during trading on Thursday. The company traded as high as GBX 5.90 and last traded at GBX 5.56. 2,739,277 shares traded hands during trading, an increase of 154% from the average daily volume of 1,079,704 shares. The stock had previously closed at GBX 5.47.

Renalytix Trading Up 1.8%

The stock has a fifty day moving average of GBX 5.17 and a 200 day moving average of GBX 3.26. The company has a market capitalization of £37.30 million, a P/E ratio of -1.39 and a beta of 1.71. The company has a debt-to-equity ratio of -483.33, a quick ratio of 2.42 and a current ratio of 1.57.

Insiders Place Their Bets

In other Renalytix news, insider Christopher H. B. Mills sold 1,166,667 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of GBX 6, for a total value of £70,000.02. Insiders own 5.99% of the company’s stock.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).